Scientists track rare brain diseases to pave way for future cures
NCT ID NCT00668187
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study follows children and adults with Tay-Sachs, Sandhoff, and GM1 gangliosidosis to understand how these diseases progress. Researchers will measure changes in motor skills, communication, and behavior each year. The goal is to create a clear picture of the diseases so future treatments, like gene therapy, can be tested effectively.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this study will provide crucial data to design future therapies and clinical trials for these rare diseases.
- What could go wrong
- This is an observational study, not a treatment trial. It does not test any intervention, so there is no direct benefit to participants.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GM1 GANGLIOSIDOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Minnesota - Pediatric Genetics and Metabolism
RECRUITINGMinneapolis, Minnesota, 55455, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a repurposed drug slow rare childhood brain diseases?
- One-Time gene therapy aims to halt rare, fatal brain disease in children
- New pill shows promise for rare brain disorders in early trial
- Small study tracks rare disease to pave way for future treatments
- New gene therapy hopes to fix fatal brain diseases
- New hope for rare brain diseases: long-term drug trial now recruiting